Q-omics provides the consensus-scored PLOD3 profile across patient tissues and cancer cell-line models. PLOD3 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, PLOD3 is differentially expressed in 16, with the highest sampling consensus in HNSC. Additionally, PLOD3 protein abundance shows 30,845 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight MESO, HNSC, and GBM as cancer lineages where PLOD3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PLOD3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PLOD3 survival associations across molecular data types. PLOD3 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (6) and mass-spec protein abundance (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PLOD3 RNA expression–survival associations across cancer types. High PLOD3 expression shows unfavorable associations in MESO, KICH, UVM, LUSC, ACC and LIHC. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for PLOD3 RNA expression.
This table summarizes PLOD3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16, while mass-spec protein shows differences in 8. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for PLOD3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PLOD3 shows higher tumor expression in HNSC, KIRC, COAD, KIRP, STAD and LIHC. The HNSC box plot shows higher PLOD3 RNA expression in tumor versus normal tissue (log2 FC = +2.390, t-test p < 0.001).
This table shows molecular features associated with PLOD3 in patient tissues and cancer cell lines. In patient samples, PLOD3 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, PLOD3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in STOMACH, while CRISPR and shRNA rows add functional-dependency signals in SKIN and BLOOD_Lymphoma.
